Multiple Sclerosis (MS)

Neurology
9
Pipeline Programs
10
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 12 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
3 programs
1
1
TecfideraPhase 42 trials
Interferon beta 1aPhase 11 trial
Konectom platformN/A1 trial
Active Trials
NCT05106465Completed200Est. Apr 2024
NCT01863069Completed77Est. Oct 2001
NCT02739542Completed87Est. Mar 2021
+1 more trials
M&
Merck & Co.RAHWAY, NJ
2 programs
1
Data CollectionPhase 41 trial
AvonexN/A1 trial
Active Trials
NCT06053749Active Not Recruiting4Est. Mar 2026
NCT03961204Completed662Est. May 2021
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
NabiximolsPhase 31 trial
Active Trials
NCT04203498Terminated139Est. Feb 2023
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
elezanumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03737851Completed208Est. Sep 2021
Teva
TevaIsrael - Petach Tikva
1 program
1
methylprednisolonePhase 21 trial
Active Trials
NCT01710228Withdrawn0Est. Dec 2013
Bristol Myers Squibb
1 program
1
11C-BMS-986196Phase 11 trial
Active Trials
NCT05064436Terminated10Est. Dec 2023
A
AnokionSwitzerland - Ecublens
1 program
1
ANK-700Phase 11 trial
Active Trials
NCT04602390CompletedEst. Apr 2024
TM
Trio MedicinesUK - London
1 program
1
Interferon beta 1aPhase 1
Novartis
NovartisBASEL, Switzerland
2 programs
AvonexN/A
Neurostatus-SMARTCAREN/A1 trial
Active Trials
NCT05575843Completed101Est. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Data Collection
BiogenTecfidera
Jazz PharmaceuticalsNabiximols
AbbVieelezanumab
Tevamethylprednisolone
Bristol Myers Squibb11C-BMS-986196
AnokionANK-700
BiogenInterferon beta 1a
Merck & Co.Avonex
NovartisNeurostatus-SMARTCARE
BiogenKonectom platform
BiogenTecfidera

Clinical Trials (12)

Total enrollment: 1,522 patients across 12 trials

NCT03961204Merck & Co.Data Collection

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Start: Aug 2019Est. completion: May 2021662 patients
Phase 4Completed
NCT02739542BiogenTecfidera

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

Start: Mar 2016Est. completion: Mar 202187 patients
Phase 4Completed
NCT04203498Jazz PharmaceuticalsNabiximols

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Start: Oct 2020Est. completion: Feb 2023139 patients
Phase 3Terminated
NCT03737851AbbVieelezanumab

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Start: Dec 2018Est. completion: Sep 2021208 patients
Phase 2Completed
NCT01710228Tevamethylprednisolone

Alternative Treatment Paradigm for Natalizumab Trial

Start: Jul 2013Est. completion: Dec 20130
Phase 2Withdrawn
NCT05064436Bristol Myers Squibb11C-BMS-986196

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Start: Dec 2021Est. completion: Dec 202310 patients
Phase 1Terminated
NCT04602390AnokionANK-700

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Start: Nov 2020Est. completion: Apr 2024
Phase 1Completed
NCT01863069BiogenInterferon beta 1a

Avonex®: Safety, Blood Levels and Effects

Start: Jan 2001Est. completion: Oct 200177 patients
Phase 1Completed
NCT06053749Merck & Co.Avonex

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Start: Mar 2024Est. completion: Mar 20264 patients
N/AActive Not Recruiting
NCT05575843NovartisNeurostatus-SMARTCARE

Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®

Start: Dec 2022Est. completion: Mar 2024101 patients
N/ACompleted
NCT05106465BiogenKonectom platform

A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

Start: Dec 2021Est. completion: Apr 2024200 patients
N/ACompleted
NCT02099370BiogenTecfidera

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

Start: Mar 2014Est. completion: Jan 201634 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
10 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)